What the bad jobs report means for markets
Tuesday, H.C. Wainwright reiterated a Buy rating and a price target of $18.00 on Enanta Pharmaceuticals (NASDAQ:ENTA) shares, significantly above the current price of $4.90. The stock is trading near its 52-week low, having declined over 60% in the past six months. According to InvestingPro data, analyst targets range from $5 to $21, with the company currently valued at $104.53 million. The research firm’s analyst, Ed Arce, provided an update on the company’s ongoing efforts in developing treatments for respiratory syncytial virus (RSV).
Enanta Pharmaceuticals recently announced the expectation of top-line data from the Phase 2b RSVHR study of zelicapavir, an RSV treatment for adults at high risk of complications. The data is anticipated in the third quarter of 2025, aligning with previous projections set to follow the current Northern Hemisphere RSV season. While the company maintains a strong liquidity position with a current ratio of 5.21, InvestingPro analysis indicates the company is quickly burning through cash, which could be crucial for the trial’s completion. The RSVHR study aims to include around 180 non-hospitalized adults who are at high risk due to factors such as being 65 years of age or older, or having congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or asthma.
In addition to the ongoing trial, Enanta is preparing to discuss zelicapavir’s registration pathway for pediatric patients with regulatory authorities. This effort is based on data from RSVPEDs, a completed Phase 2 study involving both hospitalized and non-hospitalized pediatric patients. The importance of the RSVHR study is underscored by its design to facilitate a Phase 3 trial in high-risk adults, potentially allowing zelicapavir to proceed to registration trials for two critical RSV patient groups.
Furthermore, Enanta’s management has expressed plans to explore partnership opportunities to advance its RSV programs, which include another RSV asset, EDP-323. Looking ahead to the rest of 2025, key milestones identified by H.C. Wainwright include the expected top-line readout from the RSVHR study in the third quarter and the outcomes from regulatory discussions regarding the pediatric registration pathway for zelicapavir. For deeper insights into Enanta’s financial health and growth prospects, including 10 additional ProTips and comprehensive valuation metrics, visit InvestingPro for the full research report.
In other recent news, Enanta Pharmaceuticals has been the subject of various analyst revisions and legal developments. JMP Securities reiterated a Market Outperform rating on Enanta with a steady price target of $21.00, highlighting the company’s solid financial position and ongoing projects, including the Phase 2 trial for zelicapavir.
Simultaneously, H.C. Wainwright adjusted Enanta’s price target to $18.00, maintaining a Buy rating despite the decrease. The change followed the results from Enanta’s RSVPEDs study, a Phase 2 trial involving zelicapavir.
In a legal development, Enanta faced a setback as the United States District Court of Massachusetts ruled in favor of Pfizer (NYSE:PFE) in a patent infringement lawsuit. The court declared Enanta’s patent invalid, with Enanta expressing its intention to appeal the decision.
Meanwhile, Leerink Partners increased its price target for Enanta to $12.00, while retaining a Market Perform rating. This followed Enanta’s fourth-quarter financial report, which showed lower-than-expected royalty revenues.
Lastly, Baird reduced Enanta’s price target to $20 from $26, maintaining an Outperform rating. The adjustment came after a recent earnings report and in anticipation of upcoming clinical trial results. These are the recent developments concerning Enanta Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.